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Dutch Health Council adviceRecently, the Dutch Health Council advised on elderly pneumococcal vaccination favouring the conven-
tional polysaccharide vaccine over the novel conjugated vaccine. This advice was strongly inspired by a
cost-effectiveness analysis considered to show favourable outcomes for the polysaccharide but not for
the conjugated vaccine. We argue that using the same data and methods as presented by the Health
Council, a different perspective on the results leads to a conclusion that not only the polysaccharide
but also the conjugated pneumococcal vaccine is cost-effective. Our alternative perspective concerns
the use of realistic vaccine prices, and applying an adequate time horizon for cost-effectiveness mod-
elling. Notably, for one-off vaccination of 65-years old elderly, in all investigated analyses, also the con-
jugated vaccine seems cost-effective; i.e. well below the threshold of €20,000 per quality-adjusted life
year, reflecting the most stringent threshold used for vaccines in the Netherlands.
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
A recent advice of the Dutch Health Council recommends
uptake of a pneumococcal vaccination program for elderly using
the conventional 23-valent pneumococcal polysaccharide vaccine
(PPV23) [1]. The Dutch authorities have analysed pneumococcal
vaccination several times, but so far the Netherlands had been
among the 8 out of 28 EU-countries that until recently never rec-
ommended or implemented an elderly vaccination program using
PPV23 [2]. The quest for the Health Council’s advice was also
inspired by recent local evidence that has become available on
the alternative novel 13-valent pneumococcal conjugated vaccine
(PCV13) from a large randomized clinical trial among approxi-
mately 80,000 Dutch individuals aged 65-years and over
(‘‘community-acquired pneumonia immunization trial in adults”;
CAPITA), potentially warranting a PCV13-based elderly pneumo-
coccal vaccination program [3].
As in many countries nowadays, health technology assessment
(HTA) provides a core aspect in the Dutch national authorities’
approach to advise and decide on the introduction of a new vacci-
nation campaign. Within the context of healthcare decision-
making, cost-effectiveness analysis – as one of the seven criteriafor introducing new vaccinations [4] – constitutes a crucial ele-
ment, with the cost per quality-adjusted life year (QALY) generally
as its main outcome. Informed by a separate analysis [5], the
Health Council inferred that universal elderly vaccination with
PPV23 is cost-effective, whereas PCV13 was estimated not cost-
effective, applying a strict threshold cost-effectiveness at €20,000
per QALY, a limited time horizon and officially listed prices for
individual use [1]. This result can be considered surprising as it
contradicts previous Dutch cost-effectiveness analyses on PCV13
in elderly persons [6,7], also based on CAPITA.
Here, we argue that a different view on the same economic data
would result in a different conclusion in which both vaccines could
be considered cost-effective options if a lifetime time horizon for
analysis is taken and/or realistic pricing is considered; well below
the aforementioned lowest limit for cost-effectiveness at €20,000
per QALY for the Netherlands [8]. To derive our arguments, sec-
ondary analysis on selected data from the published cost-
effectiveness study [5] was performed.
2. A broader health-economic perspective on the dutch health
council advice
With the core role for the cost-effectiveness analysis in the
Dutch recommendation for PPV23 to be implemented in a future
universal elderly pneumococcal vaccination program [1], it seems
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nomic model, evidence on the effectiveness of PCV13 against inva-
sive pneumococcal disease and pneumonia was taken from the
CAPITA-study (Table 1). For PPV23, effectiveness against IPD was
obtained from a recent meta-analysis [9], whereas for effectiveness
against pneumonia it was not possible to identify appropriate data.
An assumption based on the contribution of the PPV23 serotypes in
the overall serotype distribution in the Netherlands was made for
PPV23’s effectiveness on pneumonia. For PCV13 lasting protection
up to 15 years was assumed as well as long-term herd immunity
effects, whereas for PPV23 only short-term protection was
assumed [5]. Finally, we note that list prices were used to reflect
costs of vaccination.
Over the 10-year time horizon mostly applied in the Health
Council analyses, QALY gains for PCV13 surpass those by PPV23
with 196 as an aggregate for the whole of the Netherlands, for vac-
cinating 10 cohorts of 65-years old and measuring benefits during
those 10 years only. The corresponding cost-effectiveness esti-
mated was €44,000 per QALY for PCV13 and labelled ‘‘not cost-
effective” [5]. This relatively short time horizon of 10-years was
used, instead of the generally preferred lifetime time horizon.
Guidelines for pharmacoeconomic research recommends the life-
time time horizon (for example, the Dutch guidelines [10]) to allow
for adequate capturing of the whole spectrum of costs and benefits
[11]. Specifically, the 10-year time horizon may be considered too
short to capture all impacts of, in particular, for PCV13 with longer
lasting protective effects thus underestimating the economic value
of PCV13. Notably, in the last cohorts vaccinated in the 10-year
time period, adequate time to reap the benefits of vaccination at
all is not allowed in the model. In sensitivity analyses, the model
was evaluated over longer time frames, including lifetime. Based
on applying lifetime costs and effects, cost-effectiveness for
PCV13 was indeed estimated much lower at €15,400 per QALY
for vaccinating 65-years olds [5], below the limit of €20,000 per
QALY.
It is well known that list prices – as applied for general pharma-
cies – do not reflect the costs of vaccines for the public health
authorities within public programs. For example, costs reported
for the Dutch public authorities for PCV10 and the HPV-vaccine
included in the Dutch national vaccination program are ranging
from €17 to €23 [12], reflecting grossly 15–40% of listed prices
[13]. Obviously, the exact level of discounts provided is confiden-
tial and is likely to be dependent on the type of program, the speci-
fic disease targeted with vaccination, the availability of
competitors, the design of the tenders and the negotiation power
of the parties involved. However, that the net price will be substan-
tially below the list price seems a reasonable assumption. An
assumed price reduction of 50% would result in a cost-
effectiveness ratio of €18,900 per QALY for PCV13 (calculations
by the authors on the reported data [1,5] with a limited 10-year
time horizon).Table 1
Core assumptions in the Dutch cost-effectiveness model for PCV13 versus PPV23 [5].
PPV23 PCV13
Vaccine costs (list prices) €21.20 €72.67
Vaccine effectiveness 1st 5 years
IPD 56-0% [9]* 75% [3]
CAP 20-0% [assumed] 38% [3]
Vaccine effectiveness next 10 years
IPD 0% 75–0% [assumed]**
Pneumonia 0% 38–0% [assumed]**
*Linear decrease from year 1 to 5; **Linear decrease from maximum in 1st 5 years
to 0% in 10 years; IPD = invasive pneumococcal disease; CAP = vaccine-type hospi-
talised community-acquired pneumonia.Combining a 50% price reduction and the longer time horizon in
a secondary analysis on those data reported in the published paper
[5] resulted in cost-effectiveness ratios listed in Table 2, with var-
ious scenarios estimated in the lifetime time horizon. We build on
the scarcely reported lifetime cost-effectiveness results in the pub-
lished data [5]; i.e., two cost-effectiveness ratios (CERs) for the age
group of 65-years olds at €15,400 and €3,200 per QALY for PCV13
and PPV23, respectively (base-case estimates). Building on this
reported base-case, estimated savings and QALYs were calculated
per case averted over 10-years period and subsequently used for
estimating total savings and QALYs gained over the lifetime period
(see Annex for details on methodology). Sensitivity analysis was
performed on the savings and QALYs per case, by varying + and
25% in the estimates, to derive uncertainty intervals. As, cur-
rently, no elderly pneumococcal vaccination is performed in the
Netherlands, the comparison of PCV13 and PVV23 with absence
of vaccination - as made in the original comparison of the Health
Council – seems an appropriate one. Yet, health-economics theory
might also warrant an incremental cost-effectiveness analysis
relating the likely more expensive alternative (PCV13) to the less
expensive one (PPV23). Table 2, additionally mentions these incre-
mental cost-effectiveness ratios (ICERs). Notably, the base-case
ICER for PCV13 over PPV23 was estimated at €31,400 (uncertainty
interval: €26,100; €46,300) per QALY at baseline, and a corre-
sponding break-even price of PCV13 at €20,000 per QALY of
61.2% (50.7–69.7%) of the list price. Finally, as evidence on effec-
tiveness for community-acquired pneumonia (CAP) is scarce and
contradictory [1], we also analysed absence of effectiveness of
PPV23 on CAP, using the same secondary-data analysis methodol-
ogy as outlined above (and in the Annex).3. Discussion
It is likely that the integrative nature of the economic model is
very attractive to authorities. However, we need to stay critical
about such analysis. Above, we have shown that the same data
used for the Dutch Health Council’s advice on elderly pneumococ-
cal vaccination can – or likely should - result in a different conclu-
sion on the economic attractiveness of elderly vaccination with
PCV13. In our alternative approach, almost all analyses investi-
gated indicated a favourable cost-effectiveness of PCV13 if evalu-
ated at €20,000 per QALY. This result contrasts the Health
Council report [1] that labelled PCV13 as not-cost-effective.
We argue that the time horizon of 10 years – that was mostly
considered in the Health Council report [1,4] - is too low to capture
the full benefits of PCV13 vaccination and seems in contrast with
international guidelines that favour a long, ideally, lifetime time
horizon. Changing to a long-term time horizon acknowledges the
full benefits of PCV13 and consequently, cost-effectiveness is low-
ered to acceptable levels. Particularly, both the adequate longer
time horizon as well as expected reductions on the list price indi-
cate a cost-effectiveness for PCV13 well below the strict €20,000-
per-QALY threshold. The Health Council’s focus on the short 10-
year time horizon results, in contrast to international guidelines,
was motivated by pointing to the uncertainty in future trends
[1,5]. The issue of uncertainty raised by the authors is fair, in par-
ticular for pneumococcal epidemiology, however, should possibly
better be dealt with by applying adequate discount rates on future
health benefits and savings according to standard health-economic
theory rather than deviating from the preferred lifetime time hori-
zon. Discounting was indeed performed in the analysis according
to the Dutch health-economic guidelines. Discounting as well as
reducing the time-horizon seems like ‘‘double counting” in penal-
ising for uncertainty, which needs to be avoided. Notably, a recent
report by the National Institute for Health & Care Excellence (NICE)
Table 2
Selected exploratory scenarios from secondary data analysis on reported cost-effectiveness information [5] estimating cost-effectiveness ratios (CERs) and incremental CERs
(ICERs) in €/QALY, with corresponding uncertainty intervals. Scenarios are based on reported base-case CERs of €15,414 and €3195 for PCV13 and PPV23, respectively.
Scenarios CER PCV13 CER PPV23 ICER
1. Reduced price PCV13 €4,390 [3,217–5,202] €3,195 NA* €5,950 [3,244–8,213]
2. Reduced price both €4,390 [3,217–5,202] CS** [CS-CS] €13,364 [11,237–15,836]
3. No CAP PPV23 €15,414 NA* €12,917 [10,265–14,920] €16,771 [15,626–19,429]
4. No CAP PPV23 and reduced price PCV13 €4,390 [3,217–5,202] €12,917 [10,265–14,920] CS** [CS-1,937]
5. No CAP PPV23 and reduced price both €4,390 [3,217–5,202] €3,782 [2,516–4,995] €4,720 [2,222–6,535]
* NA: not applicable as this was the input in our back calculation process for net costs and net QALY gains in the estimation procedure outlined above;
** CS: cost saving; CAP = vaccine-type hospitalised community-acquired pneumonia; CER = cost-effectiveness ratio; ICER = incremental cost-effectiveness ratio; PCV13 = 13-
valent pneumococcal conjugated vaccine; PPV23 = 23-valent pneumococcal polysaccharide vaccine.
6284 F. Zeevat et al. / Vaccine 37 (2019) 6282–6284as well as the Joint Committee of Vaccination & Immunization
(JCVI) reinforced the use of a lifetime time horizon and adequate
discounting, in particular for vaccines [14]. Whereas a lifetime
approach may be considered optimal, already after a finite period
the vast majority of savings and health gains would be harvested.
In particular, with average life expectancy at 65 years at approxi-
mately 20 years, a time horizon of 20 years after the last cohort
considered is vaccinated could be sufficient to capture the vast
majority of benefits. This is however still far more than 10 years.
Some further analyses seem warranted. Notably, the Health
Council’s report did not follow the societal perspective as preferred
in the Dutch guidelines [10]. This perspective would, for example,
advocate inclusion of sickness leave and production losses due to
pneumonia. These can be significant for those in their sixties and
become increasingly important, considering the increasing pension
age in the Netherlands. In this respect the cost-effectiveness esti-
mates, in particular, those for PCV13 given the higher initial pro-
tection, should again be conceived as underestimates. Finally, we
note that some potentially relevant calculations were not reported
in the Dutch Health Council report and could also not be deduced
from the reported data [1,5]. A combined strategy of initial vacci-
nation with PCV13 and re-vaccination with PPV23 was not anal-
ysed but has been suggested in the literature as a potentially
cost-effective approach [15,16]. For Germany, this sequential
approach applied to all individuals at risk was estimated cost-
effective at €14,000 per QALY from the societal perspective, vary-
ing from €3,300 to €29,600 per QALY in scenario analysis [16].
In conclusion, instead of the cost-effectiveness results pre-
sented by the Dutch Health Council that favour PPV23 over
PCV13 – the latter labelled as ‘‘not cost-effective” – a more appro-
priate selection of analyses that adheres to international pharma-
coeconomic guidelines on time horizon and acknowledges
economies of scale shows that rather both vaccination strategies
have potentials of being (highly) cost-effective. Best estimates of
cost-effectiveness for PCV13 are consistently (well) below
€20,000 per QALY, which reflects an often used threshold for vac-
cines. We conclude that an adequate and consistent weighting of
the analyses of the Dutch Health Council makes PCV13 elderly vac-
cination more economically attractive than suggested, giving rise
to two potentially cost-effective options of elderly pneumococcal
vaccination in the Netherlands: both PPV23 as well as PCV13.
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